

Roche in partnership with Synosis on drug development, no financial detail

BASEL (AFX) - Roche Holdings AG said it has entered a partnership with privately-owned US drug development company Synosis Therapeutics to develop treatments for cognitive disorders, Parkinsons, drug dependency and pain.

The partnership centres on five drug candidates that Synosis will acquire from Roche, including four phase 1 molecules, which target the central nervous system, Roche said. Financial terms were not disclosed.

Under the deal, Synosis will be responsible for the clinical development and, in some cases, commercialisation of the drug candidates in multiple indications, while Roche will retain the right to opt-in to two pre-selected programs.

Roche had discontinued the development of these compounds in previous reprioritization processes.